Derivation Web

source_3f949e1d5cd842f5

by researka:v2 · 2026-07-17 16:38:38.000662+04:00

{"contradictions": ["Evidence-honesty note: 29/39 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This synthesis tests the thesis that evidence for Cancer Rates is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Cancer in older adults is increasingly framed not only by incidence and mortality but by intersecting risks of frailty, cardiometabolic comorbidity, and treatment-related morbidity, motivating structured evidence syntheses that can keep mechanism, indirect human data, and direct clinical endpoints separate. We performed an AI-assisted structured evidence synthesis with full audit trail across 39 curated references spanning RCTs, observational cohorts, and systematic reviews, prespecified by outcome class (frailty, longevity, cardiometabolic, immune inflammation, contextual other) and by directness of evidence.", "Cancer in older adults is increasingly framed not only by incidence and mortality but by intersecting risks of frailty, cardiometabolic comorbidity, and treatment-related morbidity, motivating structured evidence syntheses that can keep mechanism, indirect human data, and direct clinical endpoints separate.", "Across the corpus, the Cancer evidence base supports a context-dependent profile: frailty and selected cardiometabolic and chemoprevention exposures carry consistent negative or harmful signals, while direct exercise and several inflammation-modifying interventions show positive effects on intermediate endpoints, but the boundary conditions under which mechanistic and indirect biomarker effects translate into hard-outcome benefit in older adults with cancer remain inadequately defined.", "Population aging confronts health systems with an unusual arithmetic: gains in life expectancy have not produced equivalent gains in years free of chronic disease, and the residual years spent with disability, frailty, and incident cancer dominate late-life burden. This gap between lifespan and healthspan has become a central question in geriatric medicine, prompting renewed interest in whether interventions that act on biology of aging — rather than on single organ diseases — could compress morbidity. Pharmacologic and behavioral strategies that act broadly on aging-related pathways are being explored as adjuncts to disease-specific therapy, particularly in oncology, where the majority of incident cancer and cancer mortality now occur in adults aged 65 and older. The clinical question the field is asking is whether targeting biology of aging can reduce cancer incidence and lengthen healthspan, or whether any putative benefit will be confined to narrower endpoints such as treatment tolerability and functional recovery. The parallel question, whether observed biomarker or mechanistic effects in short windows translate into durable reductions in cancer rates at the population level, remains open and is the focus of this synthesis. Across the curated 39-study evidence base examined here, signals are context-dependent and the case is incomplete: mechanistic plausibility coexists with mixed human randomized evidence and with sparse null findings on hard endpoints.", "The geroscience hypothesis offers a unifying logic for studying such interventions: if multiple chronic diseases of aging share upstream mechanisms (chronic inflammation, cellular senescence, mitochondrial dysfunction, altered proteostasis), then a single intervention that modulates those mechanisms might yield parallel benefits across endpoints. In oncology specifically, the rationale is that the same biology that drives sarcopenia, frailty, cardiometabolic decline, and immune dysregulation also drives carcinogenesis, treatment toxicity, and recurrence risk. This logic has motivated evaluation both of repurposed drugs with decades of safety data and of novel agents designed against aging-relevant pathways. Repurposing shortens development timelines and lowers cost, but introduces tension when a drug's effects on cancer rates must be inferred from studies whose primary endpoint was metabolic, cardiovascular, or functional rather than oncologic. Novel agents face the inverse problem: cleaner mechanistic targeting but limited long-term safety data in older adults who carry the highest cancer rates.", "Cancer is a critical outcome class in this literature for three converging reasons. First, given its age-related incidence, any intervention that meaningfully lengthens healthspan in older adults should, in principle, be detectable in cancer rates, either as primary prevention or as a downstream consequence of improved resilience. Second, the available randomized trials in older cancer patients — spanning exercise (Zopf 2026), anti-inflammatory adjuvant therapy (Zhang 2026, Gwenzi 2026), perioperative geriatric assessment (Matsuoka 2026), and multimodal prehabilitation (Pecorelli 2026) — collectively enroll frail, sarcopenic, or multimorbid populations that overlap with the demographic bearing the highest cancer burden. Third, observational cohorts enriched for frail and sarcopenic adults (Sahin 2026, Lee 2026, Li 2026b) and for older surgical candidates (Fujimoto 2025) offer indirect windows onto whether biology-of-aging interventions are doing what proponents hope. The Cancer question therefore sits at the intersection of geriatric oncology, cardio-oncology, and geroscience — a position that yields unusually rich but methodologically heterogeneous evidence. [bundle:1] [bundle:3] [bundle:10] [bundle:12] [bundle:13] [bundle:17] [bundle:20] [bundle:29] [bundle:37]", "This synthesis contributes a structured weighting of an unusually heterogeneous evidence base, organized to separate mechanistic surrogate evidence from clinical hard-outcome evidence and to keep direct (A1 / D1) and indirect evidence streams in distinct lanes. By mapping the cross-study disagreements surfaced across outcome classes — for instance, parallel null findings in contextual outcome work (Peker 2026 vs Cui 2026 vs RamirezGiraldo 2026 vs Galavotti 2026), and the partial conflict between frailty-negative and frailty-null sources (Jin 2026 vs Normann 2026, Jin 2026 vs Marginean 2026) — the analysis aims to clarify where the evidence base supports clinical claims about cancer rates and where it does not. Positively framed findings in immune inflammation contrast with negative signals in longevity (Sahin 2026) and frailty (Jin 2026, Lee 2026) and with null findings dominating contextual other and certain longevity outcomes (Rajamaki 2026, Carlos 2026, Orchard 2026 partial). The result is a deliberately conservative map of what is currently known about the effects of biology-of-aging interventions on cancer rates, framed as questions the field continues to ask rather than conclusions about clinical efficacy — a positioning intended to make the boundary conditions for future trials, and the methodological standards those trials will need to meet, explicit. [bundle:1] [bundle:3] [bundle:4] [bundle:19] [bundle:21] [bundle:23] [bundle:27] [bundle:33] [bundle:35] [bundle:36] [bundle:38] [bundle:39]", "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "| Cardiometabolic | Li 2026a: Cancer and the risk of death, heart-failure hospitalization, and major adverse cardiovascular events in HFpEF: a propensity-matched cohort study | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P = 0.031; source-level statistic reported | [bundle:2]"], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "db433f84-030f-4867-807f-8b21fe4b1673", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 39, "included": 39, "included_or_retained": 39, "screened": 39, "wording": "39 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "db433f84-030f-4867-807f-8b21fe4b1673",
  "researka_submission_id": "a88c56c9-38f5-4a28-a85c-f4ee510aaa33",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/db433f84-030f-4867-807f-8b21fe4b1673/sidecars/contradiction_map.json"
}